Luteinizing Hormone Releasing Hormone and Analogues: Conceptive and Contraceptive Potential

Corbin, Alan; Bex, Frederick J.

doi:10.1007/978-94-011-7712-2_4

Cited by 8 publications

(2 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progesterone secretion was tran-siently, but not consistently, increased and declined after repeated dose administration. This is due to LH receptor down-regulation in the corpus luteum activated by supraphysiological LH release (Corbin & Bex, 1980;Fraser, 1981;. In experimental animals, a reduction in luteal LH receptors causes insufficient gonadotrophin utilisation despite pituitary stimulation by agonists.…”

Section: O R P U S L U T E U M F U N C T I O Nmentioning

confidence: 99%

“…The experimental literature on this topic is extensive and controversial, because multiple mechanisms of contraceptive action are activated with increasing doses. Pre-coital and post-coital contraceptive regimens have been proposed, based on findings in experimental animals (for reviews, see Corbin & Bex, 1980;Fraser, 1981;Sandow et al, 1981;. These applications require different dosage forms and schedules of administration.…”

Section: Contraceptionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Applications of LHRH and Its Analogues

Sandow

1983

Clinical Endocrinology

150

View full text Add to dashboard Cite

The physiological requirement for activation of pituitary gonadotrophin secretion by pulsatile LHRH stimulation is discussed, and compared with the effect of pituitary stimulation by LHRH agonists. Initial stimulation is followed by a phase of progressive pituitary and gonadal inhibition. This inhibition is fully reversible at the end of agonist treatment. Clinical applications of high dose suppression are the treatment of precocious puberty and hormone-dependent tumours (mammary and prostatic carcinoma). In women, agonist administration by nasal spray is a reversible method of inhibiting ovulation, and may also be useful in the treatment of endometriosis. Clinical advantages of agonist therapy are favourable biological tolerance, lack of side effects and rapid reversibility.

show abstract

Section: O R P U S L U T E U M F U N C T I O Nmentioning

confidence: 99%

Section: Contraceptionmentioning

confidence: 99%

Clinical Applications of LHRH and Its Analogues

Sandow

1983

Clinical Endocrinology

150

View full text Add to dashboard Cite

show abstract

In Vivo and In Vitro Investigation of the Extrapituitary Antireproductive Effects of a Potent LHRH Agonist in Immature and Adult Male Rats

Bex¹,

Corbin²

1981

Journal of Andrology

View full text Add to dashboard Cite

Co‐incubation with a potent LHRH agonist, D‐Ala6‐Des‐Gly10‐Pro9‐NHEt‐LHRH (Wy‐18, 481), did not affect testosterone or progesterone production by adult intact rat testes in vitro. Prior administration to adult intact rats in vivo (100 μg/rat/day, subcutaneously) reduced subsequent basal and hCG‐stimulated testosterone production in vitro and dramatically increased progesterone production. Similar chronic administration of the agonist in vivo to adult hypophysectomized (hypx) rats also depressed testosterone production in vitro but had no effect on that of progesterone. Using dosages which produce marked inhibition of the weights of the testes and of accessory reproductive glands in both immature and adult intact rats, long‐term (up to 28 days) treatment with Wy‐18, 481 slightly potentiated the atrophy of the testes and of the seminal vesicles due to hypophysectomy in the immature rat but had no apparent effect in the hypx adult. Concurrent administration of Wy‐18, 481 did not affect the support provided to the reproductive organs by dihydrotestosterone replacement in either immature or adult hypx rats. These results suggest that extended exposure is required to elicit direct effects of the agonist on testicular function and that these effects, which involve interference with steroidogenesis and not steroid action, differ qualitatively in the hypx animals from those occurring In the presence of the pituitary. Moreover, there appears to be an age‐related difference in sensitivity to the direct effect of the agonist.

show abstract

Manipulation of the Ovarian Cycle

Baird¹

1992

Infertility

View full text Add to dashboard Cite

Luteinizing Hormone Releasing Hormone and Analogues: Conceptive and Contraceptive Potential

Cited by 8 publications

References 140 publications

Clinical Applications of LHRH and Its Analogues

Clinical Applications of LHRH and Its Analogues

In Vivo and In Vitro Investigation of the Extrapituitary Antireproductive Effects of a Potent LHRH Agonist in Immature and Adult Male Rats

Manipulation of the Ovarian Cycle

Contact Info

Product

Resources

About